Skip to content
Credit reportVerdict and grounds
Made on 20-11-2026 at 17:28
Reference CK-0743948725-20261120

VM Pharma

ActivePrivate limited company0743.948.725Théophile Vander Elststraat 42, 1170 Watermael-Boitsfort
Retail sale of pharmaceutical products (NACE 47730) · founded in 2020 · one director · accounts in the micro format

Sources: the KBO register on 20-11-2026; the National Bank, 2025 annual accounts filed on 04-08-2026; the Belgian Official Gazette, latest deed of 25-02-2020.

Credit verdict
Checked score 2025
The score, from 0 to 100, reflects the bankruptcy probability and the standing among sector peers.
Bankruptcy probability within 12 months
The median of 40,304 micro companies in the retail trade sector (NACE 47) is 0.6%.
Gross margin
€131,435
▼ 24.8% against 2024
Net result
-€17,906
€14,987 in 2024
Equity
€242,551
▼ 6.9% against 2024
Cash
€54,967
▲ over 5.8 times that of 2024

Grounds

the facts the verdict rests on, each with its source
  1. In 2025, VM Pharma made a loss of €17,906.Annual accounts 2025 page 2
  2. Equity stands at €242,551, or 45.9% of the balance sheet total of €528,725. The solvency of 45.9% is higher than at 61% of the 25,414 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
  3. The 2025 accounts reached the National Bank on 04-08-2026, 4 days after the term.National Bank, filing of 04-08-2026 page 4

Representation

The signing rule is in the deed of 25-02-2020.

Articles of association, Belgian Official Gazette of 25-02-2020, deed 20311301

Ownership

The accounts in the micro format list no shareholders. holds all 100 shares.

Deed of 25-02-2020

VM Pharma · 0743.948.725 · credit report of 20-11-2026Page 1 of 5
VM Pharma0743.948.725 · report of 20-11-2026

Financial situation

Annual accounts 2021 to 2025, as filed with the National Bank

Gross margin and net resultin euro

2021105,9782022213,1802023131,5232024174,7402025131,435202134,607202292,490202328,895202414,9872025-17,906
gross marginnet result

Equity and debtsin euro

20212022202320242025242,551286,174
equitydebts

Cashin euro

202142,2552022126,714202324,82820249,415202554,967
on the balance sheet date
Financial year20212022202320242025Trend
Results
Gross margin€105,978€213,180€131,523€174,740€131,435
Operating result€50,234€127,142€41,682€86,990€31,565
Net result€34,607€92,490€28,895€14,987-€17,906
Balance sheet at the closing date
Equity€124,125€216,574€245,470€260,457€242,551
Debts€190,736€237,520€169,261€131,987€286,174
Debts due after more than one year€116,460€98,299€79,932€61,355€42,565
Debts due within one year€74,276€139,221€89,329€70,632€243,609
Cash€42,255€126,714€24,828€9,415€54,967
Balance sheet total€314,860€454,095€414,731€392,444€528,725
Ratios
Solvency39.4%47.7%59.2%66.4%45.9%
Liquidity2.222.273.153.871.77

Source: Annual accounts 2025, micro format, filed on 04-08-2026 (2026-00383885); Annual accounts 2024, micro format, filed on 24-06-2025 (2025-00189923); Annual accounts 2021 to 2023, filed from 22-06-2022 to 17-06-2024 (2022-20080380, 2023-00172876, 2024-00155512).

The operating result of 2025 is €31,565, the net result a loss of €17,906.

Debts rose by €154,187 in 2025, of which €139,802 to suppliers.

The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.

VM Pharma states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €174,740 to €131,435.

VM Pharma · 0743.948.725 · credit report of 20-11-2026Page 2 of 5
VM Pharma0743.948.725 · report of 20-11-2026

Board, signature and ownership

Position on 20-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts

Who represents the company

The signing rule is in the deed of 25-02-2020.

Articles of association, Belgian Official Gazette of 25-02-2020, deed 20311301

Board

one director in office
Directorappointed by deed of 25-02-2020
term without a fixed enddeed of 25-02-2020

Ownership and group

Shareholders

The accounts in the micro format list no shareholders. holds all 100 shares.

Deed of 25-02-2020

VM Pharma · 0743.948.725 · credit report of 20-11-2026Page 3 of 5
VM Pharma0743.948.725 · report of 20-11-2026

Events and comparison

Every event since the founding, newest first

Annual accounts 2025 filed, 4 days late.

NBB filing

Weakest financial year. The net result drops to -€17,906, the lowest from 2020 to 2025.

Financial

Annual accounts 2024 filed, 37 days before the deadline.

NBB filing

Annual accounts 2023 filed, 44 days before the deadline.

NBB filing

Annual accounts 2022 filed, 32 days before the deadline.

NBB filing

Highest result from 2020 to 2025. The operating result of €127,142 and the net result of €92,490 are both a record.

Financial

Equity above €200,000. With a profit in every financial year since 2020, equity grows to €216,574.

Financial

Annual accounts 2021 filed, 39 days before the deadline.

NBB filing

Equity above €100,000. With a profit in every financial year since 2020, equity grows to €124,125.

Financial

Annual accounts 2020 filed, 27 days late.

NBB filing

Incorporation. Founding capital of €50,000, 100 shares. Founded by . appointed as director. Published on 25-02-2020.

Gazette, deed 20311301

First establishment. Théophile Vander Elststraat 42, Watermael-Boitsfort.

Comparable companies, two years later

In July 2024, 930 companies had the same profile as VM Pharma has now: small, 5 to 10 years old, solvency 30% or more and a small loss. Two years later 92.7% were still trading, 5.6% had stopped another way and 1.7% had gone bankrupt.

still trading 92.7% stopped another way 5.6% bankrupt 1.7%

The return on assets of VM Pharma, -3.4%, is higher than at 26% of the 24,603 companies filing micro accounts in retail trade (NACE 47) in 2025.

Other findings

Peppol

Reachable for e-invoices since 23-09-2025, under 0208:0743948725.

Sanctions lists

VM Pharma · 0743.948.725 · credit report of 20-11-2026Page 4 of 5
VM Pharma0743.948.725 · report of 20-11-2026

Sources and method

Where each fact in this report comes from

SourceWhatDateReference
KBO registerRegistration, legal situation, activity, establishment units20-11-2026KBO 0743.948.725
National Bank of BelgiumAnnual accounts 2025, micro format04-08-20262026-00383885
National Bank of BelgiumAnnual accounts 2024, micro format24-06-20252025-00189923
National Bank of BelgiumAnnual accounts 2021 to 202322-06-2022 to 17-06-20242022-20080380, 2023-00172876, 2024-00155512
Belgian Official GazetteArticles of association with the signing rule25-02-2020deed 20311301
Peppol DirectoryRegistration for e-invoices23-09-20250208:0743948725
Sanctions lists EU, UN, US (OFAC) and UKComparison of the name19-11-2026
CheckedChecked score, bankruptcy probability, credit, comparable companies19-11-2026bankruptcy model of 2 October 2026

Method

Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.

Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 19-11-2026.

Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.

Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.

The scores and ratios are Checked's own calculations, not a credit decision.

VM Pharma · 0743.948.725 · credit report of 20-11-2026Page 5 of 5